Halozyme suffered a setback in November when its investigational pancreatic drug failed a Phase 3 clinical trial, but its CEO says the biotech’s drug delivery technology will make the company profitable as early as the second quarter of this year.

The San Diego-based company’s technology, called Enhanze, allows some drugs traditionally given intravenously over hours to be delivered instead by subcutaneous injection in minutes.

“There was a lot of passion in the company for this mission for pancreatic cancer patients, so there was a lot of disappointment that it didn’t work, but we’d been very clear on the business strategy… Read more »

UNDERWRITERS AND PARTNERS